Anti-Spike Protein [CV1]
Ab02018-15.0
ApplicationsFlow Cytometry, ELISA, Neutralisation/Blocking
Product group Antibodies
Overview
- SupplierAbsolute Antibody
- Product NameAnti-Spike Protein [CV1]
- Delivery Days Customer7
- Application Supplier NoteThis antibody is recommended for diagnosis and/or treatment of SARS CoV 2 or 2019-nCoV. CV1 binds an epitope outside the SARS CoV 2 RBD was found to be weakly neutralizing (IC50=15microg/ml). ELISA was used to confirm the binding of SARS CoV 2 positive serum samples to the entire ectodomain and the receptor binding domain of the spike protein. Specific binding of the mAb to SARS CoV 2 to ectodomain was confirmed with biolayer interferometry. Phycoerythrin labelled mAb was used to stain 293E cells transfected with wild type SARS CoV 2 and were analysed by flow cytometry (Seydoux et al., 2020).
- ApplicationsFlow Cytometry, ELISA, Neutralisation/Blocking
- CertificationResearch Use Only
- Scientific DescriptionThis reformatted human antibody was made using the variable domain sequences of the original Human IgG1 format, for improved compatibility with existing reagents, assays and techniques.
- Storage Instruction-20°C,2°C to 8°C
- UNSPSC12352203